Literature DB >> 17325273

Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker.

Randall J Bateman1, Guolin Wen, John C Morris, David M Holtzman.   

Abstract

OBJECTIVE: To investigate the stability and time course of human CSF amyloid-beta (Abeta) levels over hours.
METHODS: Fifteen nondemented participants had CSF sampled hourly for up to 36 hours via indwelling lumbar catheter. CSF Abeta(1-x), Abeta(1-40), and Abeta(1-42) were measured by ELISA in each hourly CSF sample.
RESULTS: Significant variation in Abeta levels of 1.5- to fourfold was detected over 36 hours of serially sampling in individual subjects. Abeta(40), Abeta(42), and Abeta(1-X) are highly correlated over time indicating that similar processes likely regulate the level of these species. On average, the fluctuations of Abeta levels appear to be time of day or activity dependent.
CONCLUSION: Diagnostic and therapeutic trials that measure Abeta should control for the time of CSF sampling to minimize variability.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17325273     DOI: 10.1212/01.wnl.0000256043.50901.e3

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  105 in total

1.  Predicting conversion from mild cognitive impairment to Alzheimer's disease using neuropsychological tests and multivariate methods.

Authors:  Robert M Chapman; Mark Mapstone; John W McCrary; Margaret N Gardner; Anton Porsteinsson; Tiffany C Sandoval; Maria D Guillily; Elizabeth Degrush; Lindsey A Reilly
Journal:  J Clin Exp Neuropsychol       Date:  2010-08-13       Impact factor: 2.475

2.  Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD.

Authors:  Hong I Wan; J Steve Jacobsen; J Lynn Rutkowski; Giora Z Feuerstein
Journal:  Clin Transl Sci       Date:  2009-06       Impact factor: 4.689

3.  Rostrocaudal dynamics of CSF biomarkers.

Authors:  Andrew Tarnaris; Ahmed K Toma; Miles D Chapman; Axel Petzold; Geoff Keir; Neil D Kitchen; Laurence D Watkins
Journal:  Neurochem Res       Date:  2010-12-30       Impact factor: 3.996

Review 4.  Vascular basis for brain degeneration: faltering controls and risk factors for dementia.

Authors:  Raj N Kalaria
Journal:  Nutr Rev       Date:  2010-12       Impact factor: 7.110

Review 5.  Laboratory biomarkers in Alzheimer's disease.

Authors:  Joshua R Steinerman; Lawrence S Honig
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

Review 6.  The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives.

Authors:  Russell H Swerdlow; Jeffrey M Burns; Shaharyar M Khan
Journal:  Biochim Biophys Acta       Date:  2013-09-23

Review 7.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

Review 8.  Role of HIV in amyloid metabolism.

Authors:  Mario Ortega; Beau M Ances
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-10       Impact factor: 4.147

9.  Analysis of a compartmental model of amyloid beta production, irreversible loss and exchange in humans.

Authors:  Donald L Elbert; Bruce W Patterson; Randall J Bateman
Journal:  Math Biosci       Date:  2014-12-09       Impact factor: 2.144

10.  β-amyloid dynamics in human plasma.

Authors:  Yafei Huang; Rachel Potter; Wendy Sigurdson; Tom Kasten; Rose Connors; John C Morris; Tammie Benzinger; Mark Mintun; Tim Ashwood; Mats Ferm; Samantha L Budd; Randall J Bateman
Journal:  Arch Neurol       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.